Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;117(5):641-646.
doi: 10.1111/vox.13239. Epub 2022 Jan 12.

Are convalescent plasma stocks collected during former COVID-19 waves still effective against current SARS-CoV-2 variants?

Daniele Focosi  1 , Massimo Franchini  2 , Michael J Joyner  3 , Arturo Casadevall  4
Affiliations
Review

Are convalescent plasma stocks collected during former COVID-19 waves still effective against current SARS-CoV-2 variants?

Daniele Focosi et al. Vox Sang. 2022 May.

Abstract

COVID-19 convalescent plasma (CCP) was among the few frontline therapies used to treat COVID-19. After large randomized controlled trials (RCTs) relying on late use in hospitalized patients and/or low antibody titres failed to meet their predefined primary endpoint, the infectious disease community reduced usage of CCP in favour of monoclonal antibodies. Consequently, there are CCP stocks at most transfusion centres worldwide, although scattered usage continues. Further, better designed RCTs are also being launched. The urgent question here is: should we use CCP units collected months before given the largely changed viral variant landscape? We review here in vitro evidence that discourages usage of such CCP units against Delta and other variants of concern. CCP collections should be continued in order to update the armamentarium of therapeutics against vaccine breakthrough infections or in unvaccinated patients and is especially relevant in next-generation RCTs.

Keywords: COVID-19 convalescent plasma; SARS-CoV-2; variants of concern.

Similar articles

See all similar articles

Cited by

  • How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?
    Bloch EM, Tobian AAR, Shoham S, Hanley DF, Gniadek TJ, Cachay ER, Meisenberg BR, Kafka K, Marshall C, Heath SL, Shenoy A, Paxton JH, Levine A, Forthal D, Fukuta Y, Huaman MA, Ziman A, Adamski J, Gerber J, Cruser D, Kassaye SG, Mosnaim GS, Patel B, Metcalf RA, Anjan S, Reisler RB, Yarava A, Lane K, McBee N, Gawad A, Raval JS, Zand M, Abinante M, Broderick PB, Casadevall A, Sullivan D, Gebo KA. Bloch EM, et al. Transfusion. 2022 May;62(5):933-941. doi: 10.1111/trf.16871. Epub 2022 Apr 4. Transfusion. 2022. PMID: 35352362 Free PMC article.
  • Convalescent plasma in outpatients with COVID-19.
    Focosi D, Casadevall A. Focosi D, et al. Lancet Respir Med. 2022 Mar;10(3):226-228. doi: 10.1016/S2213-2600(22)00050-9. Epub 2022 Feb 9. Lancet Respir Med. 2022. PMID: 35150608 Free PMC article. No abstract available.

References

REFERENCES

    1. Kunze KL, Johnson PW, van Helmond N, Senefeld JW, Petersen MM, Klassen SA, et al. Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors. Nat Commun. 2021;12:4864.
    1. WHO. WHO: Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (2021). Accessed 14 Sept 2021.
    1. PANGO Network New AY lineages. https://www.pango.network/summary-of-designated-ay-lineages/. Accessed 27 Dec 2021.
    1. Focosi D, Mazzetti P, Pistello M, Maggi F. Viral infection neutralization tests: a focus on SARS-CoV-2 with implications for convalescent plasma therapy. Rev Med Virol. 2020;31:e2170.
    1. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent plasma antibody levels and the risk of death from COVID-19. N Engl J Med. 2021;384:1015-27.

Substances

Supplementary concepts